Advisors Capital Management LLC purchased a new stake in Core Laboratories Inc. (NYSE:CLB - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 237,398 shares of the oil and gas company's stock, valued at approximately $2,766,000. Advisors Capital Management LLC owned 0.52% of Core Laboratories as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in the stock. Summit Securities Group LLC acquired a new stake in shares of Core Laboratories in the first quarter valued at $31,000. Aster Capital Management DIFC Ltd purchased a new stake in Core Laboratories during the 4th quarter worth approximately $34,000. Quarry LP lifted its holdings in Core Laboratories by 118.1% during the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company's stock worth $36,000 after buying an additional 1,599 shares in the last quarter. CWM LLC boosted its position in Core Laboratories by 36.1% in the 4th quarter. CWM LLC now owns 2,516 shares of the oil and gas company's stock valued at $40,000 after buying an additional 668 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in Core Laboratories by 124.7% in the 4th quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company's stock valued at $51,000 after buying an additional 1,763 shares during the period. 97.81% of the stock is currently owned by institutional investors and hedge funds.
Core Laboratories Stock Performance
Shares of CLB opened at $12.61 on Friday. The company has a quick ratio of 1.55, a current ratio of 2.12 and a debt-to-equity ratio of 0.41. Core Laboratories Inc. has a 52-week low of $9.79 and a 52-week high of $20.36. The company has a 50-day simple moving average of $11.52 and a 200-day simple moving average of $14.46. The company has a market capitalization of $578.55 million, a PE ratio of 22.52, a P/E/G ratio of 2.83 and a beta of 1.03.
Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The firm had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. During the same quarter in the previous year, the firm earned $0.19 earnings per share. The firm's revenue was down 4.3% on a year-over-year basis. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Equities research analysts predict that Core Laboratories Inc. will post 0.56 earnings per share for the current fiscal year.
Core Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be given a dividend of $0.01 per share. The ex-dividend date is Monday, August 10th. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. Core Laboratories's payout ratio is presently 7.14%.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. Weiss Ratings raised Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Johnson Rice upgraded Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 price target on the stock in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $21.00.
Check Out Our Latest Analysis on CLB
Insider Activity at Core Laboratories
In other Core Laboratories news, CEO Lawrence Bruno acquired 5,000 shares of the company's stock in a transaction dated Friday, July 31st. The stock was acquired at an average cost of $10.78 per share, with a total value of $53,900.00. Following the purchase, the chief executive officer directly owned 262,438 shares in the company, valued at approximately $2,829,081.64. This trade represents a 1.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.26% of the stock is owned by corporate insiders.
About Core Laboratories
(
Free Report)
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company's portfolio spans two primary service lines: reservoir description and production enhancement.
Featured Articles
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories Inc. (NYSE:CLB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
